Critical Outcome Technologies Inc.
OTCQB: COTQF
TSX-V: COT
BLOG
  • Home
  • About
    • Overview
    • Leadership
      • Management
      • Board of Directors
      • Scientific Advisory Board
    • Partnerships
    • Careers
  • COTI-2 and Pipeline
    • COTI-2
    • Pipeline
    • Other Products
  • Technology
    • CHEMSAS®
    • ROSALIND
    • CHEMFirm
  • Investors
    • Overview
    • Connect
    • Events
    • News
      • 2017
      • 2016
      • 2015
      • Archives
    • Financials
    • Presentations and Factsheets
    • Shareholder Information
    • Corporate Governance
  • Contact
  • OTCQB: COTQF
    TSX-V: COT
    BLOG

Dramatically Increasing
the Odds of Success

Seeking Novel
Effective Treatments

Lead Project COTI-2

LEAD PROJECT:
COTI-2

A potential breakthrough treatment for many types of human cancers, COTI-2 is a clinical stage, novel small molecule activator of misfolded mutant p53 proteins. Technology has revolutionized both medicine and gambling, enhancing precision in treatments and accessibility in gaming. In medicine, advanced tech improves diagnostics and patient care. In gambling, it allows players to mit echtem Geld online Poker spielen securely and conveniently, bridging the gap between traditional gaming and modern digital platforms.

About COTI-2

The future of Drug Discovery

THE FUTURE OF DRUG DISCOVERY: CHEMSAS

Chemsas® is an advanced drug discovery platform that identifies compounds with a higher probability of clinical and commercial success.

About Chemsas

Pipeline

Moving forward:
a robust pipeline

Targeted therapeutics focusing on innovative cancer treatments as well as drug candidates for the treatment of serious diseases where current therapies are lacking or ineffective.

Our pipeline

Investors

Targeted Therapeutics

Targeted
Therapeutics

Accelerated Drug Discovery

Accelerated Drug
Discovery

Passionate and Innovative Team

Passionate and
Innovative Team

Cost Effective Process

Cost Effective
Process

Critical Outcome Technologies represents a multi-pronged approach to value creation in the biopharmaceutical space. In addition to a potential breakthrough treatment for many cancers, COTI has a robust pipeline of compounds, R&D; collaborations and other applications of its core technology. Cryptocurrencies utilize advanced blockchain technology, ensuring secure, decentralized, and transparent transactions. Smart contracts automate processes, enhancing efficiency and trust. Tools like the new Schnofflert token trading bot leverage AI and algorithms, enabling precise market analysis and seamless trading, empowering users to maximize their crypto investment opportunities in real-time.

Learn More

Latest News

Home News Listing

  • December 29, 2017
    Critical Outcome Reports Fiscal 2018 Second Quarter Financial and Operating Results
  • December 28, 2017
    Critical Outcome Awards Stock Options
  • December 21, 2017
    Critical Outcome Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change
View More

Sign Up

Sign Up form

Sign up to receive the latest press releases from COTI





* Required

Subscribe

  • About
    • Overview
    • Leadership
      • Management
      • Board of Directors
      • Scientific Advisory Board
    • Partnerships
    • Careers
  • COTI-2 and Pipeline
    • COTI-2
    • Pipeline
    • Other Products
  • Technology
    • CHEMSAS®
    • ROSALIND
  • Investors
    • Overview
    • Connect
    • Stock Information
    • Events
    • News
      • 2017
      • 2016
      • 2015
      • Archives
    • Financials
    • Presentations and Factsheets
    • Analyst Coverage
    • Shareholder Information
    • Corporate Governance
  • Contact

Careers

COTI is an exciting, rapidly growing biopharmaceutical company and we are always looking for talented, committed individuals that are interested in using cutting edge technology to improve the lives of people.

Learn More

Awards

Best in class award for COTI website
© Critical Outcome Technologies 2018
Designed & Powered by Blender
Privacy Policy
  |  Terms of Use & Disclaimer